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Abstract
Liver fibrosis is a complex inflammatory and fibrogenic process that results from chronic 
liver injury and represents an early step in the progression of cirrhosis. Several cell types 
[hepatic stellate cells (HSCs), hepatocytes, liver sinusoidal endothelial cells (LSECs), and 
Kupffer cells (KCs)], cytokines [platelet-derived growth factor (PDGF), transforming 
growth factor (TGF)-β, tumor necrosis factor (TNF)-α, interferons (IFNs), interleukins 
(ILs)], oxidative stress, and microRNAs (miRNAs) are involved in the initiation and pro-
gression of liver fibrosis/cirrhosis. Generally, liver fibrosis begins with the stimulation of 
inflammatory immune cells to secrete cytokines, growth factors, and other activator mol-
ecules. These chemical mediators direct HSCs to activate and synthesize large amounts 
of extracellular matrix (ECM) components. Therefore, HSC activation is a pivotal event 
in the development of fibrosis and a major contributor to collagen (specifically type I) 
accumulation. The inhibitory effect of halofuginone on collagen type α1(I) synthesis and 
ECM deposition has been shown in several experimental models of fibrotic diseases. 
Halofuginone inhibits TGF-β–induced phosphorylation of Smad3, which is a key phe-
nomenon in the fibrogenesis. It also regulates cell growth and differentiation, apoptosis, 
cell migration, and immune cell function in liver fibrosis/cirrhosis. This review discusses 
the etiology and mechanisms of liver fibrosis/cirrhosis and the promising role of anti-
fibrotic agent halofuginone.
Keywords: liver fibrosis, liver cirrhosis, hepatic stellate cells, pathogenesis, anti-fibrotic, 
halofuginone
1. Introduction
Liver cirrhosis is the end-stage condition of several chronic liver diseases, and fibrosis is the 
critical pre-stage of cirrhosis. On a worldwide perspective, liver cirrhosis can be induced by 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
a number of well-defined etiological causes/factors or conditions such as chronic infection by 
hepatitis B, C viruses, chronic alcoholism and/or chronic exposure to toxins or drugs, infec-
tions, chronic exposure to altered metabolic conditions, inherited metabolic diseases such as 
hematochromatosis and Wilson’s disease, auto-immune diseases such as primary biliary cir-
rhosis, and auto-immune hepatitis [1–3]. These etiologies may work separately or in com-
bination with each other to produce cumulative effects. While the causes of liver cirrhosis 
are multifactorial, there are some pathological characteristics that are common to all cases of 
cirrhosis, including degeneration and necrosis of hepatocytes, replacement of healthy liver 
parenchyma by fibrotic scar tissues and regenerative nodules, and loss of liver function [4–7].
Fibrosis is characterized by high levels of extracellular matrix (ECM, non-functional con-
nective tissue) components extremely rich in collagen type I. The matrix metalloproteinases 
(MMPs, matrix degradation enzymes), and the tissue inhibitor of metalloproteinases (TIMPs) 
play a crucial role in the fine regulation of ECM turnover, which is altered in most patho-
logical states associated with liver fibrosis [8]. The key cellular mediator of fibrosis comprises 
the activated hepatic stellate cells (HSCs), which serve as the primary ECM-producing cells. 
HSCs, which play a key role in the development of liver fibrosis [9, 10], are activated by sev-
eral inflammatory cytokines and growth factors in a paracrine and autocrine manner [11, 12].
Liver fibrosis and cirrhosis are dynamic and highly integrated molecular, tissue and cellular 
processes that can progress and regress over time [13] and that require cellular cross-talk 
between various liver cell types [14]. At early stages of fibrosis, initiating signals [such as 
DNA, reactive oxygen species (ROS)], responding cells [Kupffer cells (KCs), platelets, liver 
sinusoidal endothelial cells (LSECs)], and soluble mediators [such as platelet-derived growth 
factor (PDGF), transforming growth factor (TGF)-β] induce accompanying wound-healing 
responses to liver injury. With time, cells, cytokine responses, and ECM components become 
more specialized but continue to have strong interactions with each other [15].
Halofuginone is a non-toxic plant alkaloid [7-bromo-6-chloro-3-(3-hydroxy-2-piperidine)-
2-oxopropyl-4(3H)-quinazoline] isolated from the roots of Dichroa febrifuga, and is used 
worldwide as an anti-parasitic drug [16]. Independent of this effect, halofuginone was found 
to be a potent inhibitor of collagen type α1 (I) gene expression [17], which was demonstrated 
in a broad range of cell types both in vitro and in vivo [16–20]. Due to its inhibitory effects 
on collagen synthesis (collagen type α1) and ECM deposition, halofuginone treatment was 
used in several experimental disease models characterized by excessive collagen accumu-
lation, such as pulmonary, pancreatic and renal fibrosis [21–23], scleroderma and chronic 
graft-versus-host disease [24], post-operative peritendinous and abdominal adhesions [25, 
26], urethral and esophageal strictures [27, 28], wound repair [29], burn injury [30], renal 
injury [31, 32], injury-induced arterial intimal hyperplasia [33], colitis [34], and liver fibrosis 
and cirrhosis [35–39]. Although the exact anti-fibrotic mechanism of halofuginone is not well 
understood, it was found that halofuginone affects collagen synthesis probably by inhibiting 
TGF-β-mediated Smad3 (intracellular protein) activation [40]. Halofuginone also regulates 
cell growth and differentiation, apoptosis, cell migration, and immune cell function [41]. It 
prevents concanavalin A-induced liver fibrosis by affecting T helper 17 (Th17) cell differentia-
tion, which suggests a direct connection between the myofibroblasts/fibrosis pathway and 
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the Th17 pro-inflammatory pathway [38]. In addition, halofuginone treatment effectively 
inhibits the delayed-type hypersensitivity response, indicating suppression of T cell–medi-
ated inflammation in vivo [42]. Moreover, it is a potent inhibitor of nuclear factor (NF)-κB, 
pro-inflammatory cytokines and p38 mitogen-activated protein kinase (p38 MAPK) phos-
phorylation in activated T cells in vitro [42]. Also, it inhibits HSC proliferation and migration 
and up-regulates their expressions of fibrolytic MMP-3 and -13 via activation of p38 MAPK 
and NF-κB [43].
Although there are no highly effective anti-fibrogenic agents currently available, the potential 
candidates that can specifically inhibit ECM components in general and specifically inhibit 
collagen type I in particular, are considered to be promising for the prevention and treatment 
of liver fibrosis/cirrhosis. The present review aims to clarify the etiology and mechanisms of 
liver fibrosis/cirrhosis and focus on the anti-fibrotic potential of a novel and promising agent, 
halofuginone.
2. Role of different cell types in liver fibrosis/cirrhosis
The liver is composed of parenchymal cells (hepatocytes) and non-parenchymal cells (HSCs, 
LSECs, and KCs). Both parenchymal and non-parenchymal cells are involved in the initiation 
and progression of liver fibrosis/cirrhosis (Table 1).
Cell types Role in liver fibrosis/cirrhosis References
Hepatic stellate cells 
(HSCs)
Main function is storage of vitamin A and other retinoids [7, 44]
Undergo a phenotypic switch from a quiescent type into an activated type 
(myofibroblast-like cells) by several inflammatory cytokines
[46]
Activated HSCs are major contributors to collagen accumulation [47, 48]
Hepatocytes Hepatocyte-derived apoptotic bodies stimulate secretion of fibrogenic 
cytokines from KCs and promote HSC activation
[50–53]
Hypoxic hepatocytes become a primary source of TGF-β in cirrhotic stage [55]
Liver sinusoidal 
endothelial cells 
(LSECs)
Defenestration and capillarization of LSECs lead to impaired substrate 
exchange and HSC activation
[57, 61, 62]
Secrete IL-33 to activate HSCs [63]
Kupffer cells (KCs) Activated KCs secrete inflammatory cytokines, promote HSC activation, and 
stimulate cell proliferation
[65–69]
KC-derived TGF-β1 stimulates proliferation and collagen formation of HSCs [66]
Activated KCs kill HSCs by a caspase 9-dependent mechanism via TRAIL [72, 73]
Abbreviations: TGF-β, transforming growth factor-β; IL, interleukin; TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand.
Table 1. Role of different cell types in liver fibrosis/cirrhosis.
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2.1. Hepatic stellate cells (HSCs)
HSCs are one of the non-parenchymal cells of the liver located in the perisinusoidal space 
(space of Disse) between hepatocytes and sinusoidal endothelial cells. HSCs are also known 
as fat-storing cells, perisinusoidal cells, lipocytes, or vitamin A-rich cells, and their main func-
tion is storage of vitamin A and other retinoids [7, 44]. HSCs show two different phenotypes: 
quiescent type in the healthy liver and activated type in the diseased one. Quiescent HSCs 
mostly function as vitamin A reserves [45]. However, in response to liver injury, inflamma-
tory cytokines such as tumor necrosis factor (TNF)-α, TGF-β, interleukin (IL)-1, and PDGF 
promote HSCs to undergo a phenotypic switch from a quiescent, vitamin A storing cell into 
proliferative, α-smooth muscle actin (α-SMA)-positive, myofibroblast-like cells which con-
tribute to fibrosis by producing the abnormal ECM components [46]. Therefore, HSC acti-
vation is a pivotal phenomenon in initiation and progression of liver fibrosis and a major 
contributor to collagen accumulation [47, 48].
2.2. Hepatocytes
Hepatocytes are the primary parenchymal component of the liver and play an important role 
in fibrosis/cirrhosis. They are the main targets of several hepatotoxic agents including hepa-
titis viruses, alcohol metabolites, and bile acids [11]. Liver injury either promotes apoptosis 
or triggers compensatory regeneration of hepatocytes [49]. Hepatocyte-derived apoptotic 
bodies stimulate secretion of fibrogenic cytokines from KCs and promote HSC activation via 
interaction of toll-like receptor (TLR)-9 with DNA, which is released from apoptotic hepa-
tocytes [50–53]. On the other hand, activated HSCs also act as phagocytes and phagocytize 
hepatocyte apoptotic bodies, which promote myofibroblasts survival and fibrogenesis [54]. 
Therefore, apoptosis of hepatocytes is a crucial event in liver injury and contributes to tissue 
inflammation, fibrogenesis, and development of cirrhosis. Also, in the cirrhotic stage, hypoxic 
hepatocytes become a primary source of TGF-β, which may augment liver fibrosis [55].
2.3. Liver sinusoidal endothelial cells (LSECs)
LSECs constitute the sinusoidal wall, also known as endothelium, or endothelial lining. The 
main characteristic of LSECs is having the fenestrae on the surface of the endothelium [56, 57]. 
The endothelial fenestrae control exchange of fluids, solutes, and particles between sinusoidal 
blood and hepatocytes [58]. In the healthy liver, the fenestrated endothelial cells prevent HSC 
activation through vascular endothelial growth factor-stimulated nitric oxide production [59]. 
However, LSECs have high endocytotic capacity [56, 60]. Upon liver injury, defenestration 
and capillarization of LSECs lead to impaired substrate exchange which is the major cause of 
hepatic dysfunction [57, 58] and HSC activation [61, 62]. It has been also revealed that LSECs 
can secrete the cytokine IL-33 to activate HSCs and promote liver fibrosis [63].
2.4. Kupffer cells (KCs)
KCs, also called stellate macrophages, are interspersed throughout the liver, situated within 
the sinusoids. KCs are responsible for the removal of circulating microorganisms, immune 
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complexes, and debris from the blood stream. They are usually activated by many injuri-
ous factors such as viral infection and alcohol [64]. Activation of KCs is a key phenomenon 
in initiation and preservation of liver fibrosis. Activated KCs express chemokine receptors, 
secret inflammatory cytokines (such as TNF-α, IL-1, IL-6) and serve as antigen-presenting 
cells, which lead to progression of fibrosis [65–68]. KCs are also involved in the activation of 
HSCs and formation of liver fibrosis. For example, KC-conditioned medium promotes activa-
tion of cultured rat HSCs with enhanced ECM production and stimulates cell proliferation via 
induction of PDGF receptors on the membrane of HSCs [69]. KC-derived TGF-β1 stimulates 
proliferation and collagen formation of HSCs in a rat model of alcoholic liver fibrogenesis 
[66]. Moreover, macrophage ablation has been shown to attenuate liver fibrosis. For example, 
gadolinium chloride-mediated depletion of KCs has been shown to result in attenuation of 
carbon tetrachloride (CCl
4
)-induced fibrosis in rats with prevention of the increased TGF-β 
expression [70]. Conversely, KCs produce interstitial collagenase MMP-13 when treated with 
gadolinium chloride, which reduces ECM deposition during experimental liver fibrosis [71]. 
In addition, activated KCs can effectively kill HSCs by a caspase 9-dependent mechanism via 
possible involvement of TNF-related apoptosis-inducing ligand (TRAIL) [72, 73].
3. Role of cytokines in liver fibrosis/cirrhosis
Cytokines, which mediate several immune and inflammatory reactions, are small signal-
ing proteins that facilitate intercellular communication between various cells. They func-
tion through cell-surface receptors, and down-stream signaling induces an alteration of cell 
functions. Liver fibrosis/cirrhosis is a result of interaction of a complex network of cytokines, 
which modify activities of circulating immune cells, HSCs, KCs, LSECs, and hepatocytes. The 
role of cytokines in liver fibrosis/cirrhosis is summarized in Table 2.
3.1. Platelet-derived growth factor (PDGF)
PDGF is one of the most potent mitogen for HSCs isolated from mouse, rat, or human liver 
[74]. PDGF and its receptors are significantly overexpressed in fibrotic tissues, and its activity 
increases with the degree of liver fibrosis [75, 76]. Hepatocyte damage resulting from factors, 
such as viruses, chemicals, or hepatotoxins, can induce KCs to synthesize and release PDGF 
[77]. When PDGF binds to its specific receptor on the membrane of HSCs, it activates cor-
responding signal molecules and transcription factors, leading to the activation of its down-
stream target genes and activation of HSCs [74]. PDGF has been shown to up-regulate the 
expression of MMP-2, MMP-9, and TIMP-1, and inhibit collagenase activity, thereby decreas-
ing ECM degradation [78].
3.2. Transforming growth factor (TGF)-β
Among fibrotic mediators, TGF-β is one of the most important pro-fibrotic cytokine. The direct 
targets in TGF-β pathway, Smads (especially Smad3) are critical mediators in fibrogenesis [79, 80]. 
The intracellular effectors of TGF-β signaling, the Smad proteins, are activated by receptors and 
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Mediators Mechanism of action References
Platelet-derived growth factor 
(PDGF)
Activates HSCs [74]
Up-regulates expression of MMP-2, MMP-9, and TIMP-1 and 
inhibits collagenase activity
[78]
Transforming growth factor 
(TGF)-β
Stimulates HSC activation [81, 82]
Induces expression of matrix-producing genes, inhibits ECM 
degradation, and promotes TIMPs
[84, 85]
Inhibits DNA synthesis and induces apoptosis of hepatocytes [86–88]
Tumor necrosis factor (TNF)-α Induces hepatocyte death by apoptosis [90]
Activates HSCs and stimulates ECM synthesis [91, 92]
Induces/reduces apoptosis of activated HSCs [73, 93]
Reduces glutathione and inhibits pro-collagen α1 mRNA 
expression
[94]
Interferons (IFNs)
IFN-α Triggers apoptosis of HSCs [96]
Elicits an anti-apoptotic effect on activated HSCs [100]
IFN-β Decreases α-SMA and collagen expression and inhibits HSC 
activation through inhibition of TGF-β and PDGF
[97]
IFN-γ Reduces ECM deposition by inhibiting HSC activation [98]
Exerts a pro-apoptotic effect on activated HSCs [100]
Interleukins (ILs)
IL-1 Activates HSCs and stimulates them to produce MMP-9, MMP-
13 and TIMP-1
[102]
Increases MCP-1 in hepatocytes and augments TLR-4-
dependent up-regulation of inflammatory signaling in 
macrophages
[105]
IL-17 Regulates production of TGF-β1 by KCs, induces activation of 
HSCs and induces production of collagen and α-SMA in HSCs 
via STAT3 pathway
[108]
IL-6 Attenuates hepatocyte apoptosis and induces regeneration of 
hepatocytes through NF-κB pathway
[112]
IL-10 Inhibits expression of TGF-β1, MMP-2 and TIMP-1 [115]
Inhibits HSC activity [117]
Reduces TGF-β1, TNF-α, collagen α1, and TIMP mRNA 
up-regulation
[120]
IL-22 Inhibits hepatocyte apoptosis via STAT3 [121, 122]
Induces HSC senescence [123]
Abbreviations: HSC, hepatic stellate cell; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; 
ECM, extracellular matrix; SMA, smooth muscle actin; MCP, monocyte chemoattractant protein; TLR, toll-like receptor; 
KC, Kupffer cell; STAT, signal transducer and activator of transcription; NF-κB, nuclear factor-κB.
Table 2. Role of cytokines in liver fibrosis/cirrhosis.
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translocate into the nucleus, where they regulate transcription [79]. The main effect of TGF-β is 
to stimulate HSC activation, and the TGF-β autocrine cycle in activated HSCs is an important 
positive feedback to the progression of liver fibrosis [81, 82]. Though the main source of TGF-β in 
fibrotic liver is activated HSCs, LSECs, KCs, and hepatocytes also contribute to synthesis of this 
growth factor [83]. The level of TGF-β1 expression is increased during liver fibrosis and reaches 
a maximum at cirrhosis [55]. TGF-β1 induces expression of the matrix-producing genes, inhibits 
ECM degradation, and promotes TIMPs, leading to excessive collagen accumulation and pro-
moting the development of liver fibrosis [84, 85]. Furthermore, TGF-β1 has been shown to inhibit 
DNA synthesis and induces apoptosis of hepatocytes. In particular, TGF-β1-induced apoptosis 
is thought to be responsible for tissue loss and decrease in liver size seen in cirrhosis [86–88].
3.3. Tumor necrosis factor (TNF)-α
TNF-α is a pro-inflammatory cytokine produced by different cell types. However, it is mainly 
produced by activated KCs in the liver. TNF-α is an important mediator in several processes 
such as cell proliferation, inflammation, and apoptosis [89]. TNF-α can induce cell death by 
apoptosis, and KCs can be stimulated by apoptotic hepatocytes to produce more TNF-α [90]. 
Furthermore, TNF-α plays an essential role in the HSC activation and ECM synthesis in liver 
fibrosis [91, 92]. TNF-α may act as surviving factor for activated rat HSCs by up-regulating 
the anti-apoptotic factors (NF-κB, bcl-xL, and p21WAF1) and by down-regulating the pro-
apoptotic factor (p53) [93]. On the other hand, TNF-α can induce apoptosis in HSCs [73]. It 
has been also demonstrated that TNF-α shows anti-fibrogenic effect in rat HSCs by reducing 
glutathione and inhibiting pro-collagen α1 mRNA expression [94].
3.4. Interferons (IFNs)
IFNs are potent pleiotropic cytokines that broadly alter cellular functions in response to viral 
and other infections. Leukocytes synthesize IFN-α and IFN-β in response to viruses, and T 
cells secrete IFN-γ upon stimulation with various antigens and mitogens. Although the pri-
mary action of IFN-α is to eradicate viruses, patients with hepatitis C treated with IFN-α 
exhibit a regression of liver fibrosis even if viral eradication is not achieved [95], indicating 
that IFN-α itself has anti-fibrotic activity via triggering the apoptosis of HSCs [96]. IFN-β treat-
ment decreases α-SMA and collagen expression and inhibits HSC activation through inhibi-
tion of TGF-β and PDGF pathways [97]. Similarly, IFN-γ reduces ECM deposition in vivo 
by inhibiting HSC activation [98] via TGFβ1/Smad3 signaling pathways [99]. Interestingly, 
IFN-α and IFN-γ may exert opposite effects on apoptosis in HSCs. IFN-α was shown to elicit 
an anti-apoptotic effect on activated HSCs, whereas IFN-γ was found to exert pro-apoptotic 
effect on HSCs by down-regulating heat-shock protein 70 [100].
3.5. Interleukins (ILs)
ILs are immunomodulatory cytokines that are critically involved in the regulation of immune 
responses. They are produced by a variety of cell types such as CD4+ T lymphocytes, mono-
cytes, macrophages, and endothelial cells. KCs and LSECs can rapidly produce ILs in response 
to liver injury. ILs can have pro- and anti-inflammatory functions in chronic liver diseases, 
dependent on the inflammatory stimulus and, the producing and the responding cell type.
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The main function of pro-inflammatory ILs is to stimulate immune responses that result in the 
elimination of invading pathogens or damaged cells. On the other hand, anti-inflammatory 
ILs are produced to protect the host’s body from exaggerated immune responses and to limit 
organ damage. As soon as the pathogenic stimuli are removed, ILs production is no longer 
needed, and inflammation diminishes. If the stimulus continues, inflammation can become 
chronic and induce a variety of inflammatory diseases [101].
IL-1 is a pro-inflammatory and pro-fibrotic cytokine that directly activates HSCs and stimu-
lates them to produce MMP-9, MMP-13, and TIMP-1, resulting in liver fibrogenesis [102]. IL-1 
receptor-deficient mice exhibits ameliorated liver damage and reduced fibrogenesis [102]. 
Similarly, IL-1 receptor antagonist protects rats from developing fibrosis in dimethylnitrosa-
mine-induced liver fibrosis [103]. Lack of IL-1α or IL-1β also makes the mice less susceptible 
to develop liver fibrosis in experimental model of steatohepatitis [104]. It has been also shown 
that IL-1β at physiological doses increases the inflammatory and prosteatotic chemokine 
monocyte chemoattractant protein (MCP)-1 in hepatocytes, and augments TLR-4-dependent 
up-regulation of inflammatory signaling in macrophages [105]. Thus, IL-1 is an important 
participant, along with other cytokines, and controls the progression from liver injury to 
fibrogenesis.
Another pro-inflammatory and pro-fibrotic cytokine IL-17 has been reported to be involved 
in many immune processes, most notably in inducing and mediating pro-inflammatory 
responses. Its expression increases with increasing degree of liver fibrosis [106, 107], suggest-
ing that IL-17 may not only induce inflammation but also contribute to disease progression 
and chronicity [106]. IL-17 regulates production of TGF-β1 by KCs, which in turn, induces acti-
vation of HSCs into myofibroblasts, and further facilitates differentiation of IL-17 expressing 
cells [108]. Also, IL-17 directly induces production of collagen and α-SMA in HSCs via the sig-
nal transducer and activator of transcription (STAT)3 signaling pathway [108]. Furthermore, 
abrogation of IL-17 signaling by deletion of IL-17RA protects mice from fibrogenesis [108]. 
Similarly, blockade of endogenous IL-17 with neutralizing IL-17-specific antibody reduces 
liver fibrosis, whereas treatment with recombinant IL-17 increases fibrosis development [109].
IL-6 is a pleiotropic cytokine, which may affect differentiation of fibroblast to myofibroblast, 
and it plays an important role in fibrotic diseases [110, 111]. On the other hand, IL-6 has ben-
eficial effects for the liver. For example, IL-6 reduces CCl
4
-induced acute and chronic liver 
injury and fibrosis [112]. Also, it attenuates hepatocyte apoptosis and induces regeneration of 
hepatocytes through NF-κB signaling pathway [112]. In an experimental model of concava-
line A-induced hepatitis, IL-6 pretreatment protects mice from liver injury. This protection 
requires gp130 signaling in hepatocytes and is mediated via the gp130/STAT3 signaling cas-
cade [113]. Furthermore, systemic injection of IL-6 followed by intrahepatic transplantation 
of mesenchymal stem cells is also able to reduce hepatocyte apoptosis and liver fibrogenesis 
after CCl
4
 treatment [114].
IL-10 is one of the major anti-inflammatory cytokines, with tissue protective functions during 
fibrogenesis. It down-regulates the pro-inflammatory response and has a modulatory effect 
on liver fibrogenesis [115, 116]. IL-10 has been shown to exert anti-fibrotic effects through 
inhibiting HSC activity [117]. IL-10-deficient mice show higher liver fibrosis with larger 
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inflammatory infiltrates in CCl
4
-induced liver fibrosis compared to wild-type mice [118, 119]. 
IL-10 gene therapy reverses CCl
4
-induced murine liver fibrosis by inhibiting the expression 
of TGF-β1, MMP-2, and TIMP-1 [115]. Additionally, IL-10 gene therapy reverses liver fibrosis 
and prevents cell apoptosis in a thioacetamide-treated murine liver, and reduces TGF-β1, 
TNF-α, collagen α1, and TIMP mRNA up-regulation, suggesting a therapeutic potential for 
treatment with IL-10 [120].
IL-22 is known to play important roles in the modulation of tissue immune responses to 
inflammation. It reduces inflammation-induced damage of hepatocytes both in vitro and in 
vivo by promoting their survival and inhibiting apoptosis [121]. This protective function is 
dependent on STAT3 signaling, as STAT3-deficient mice were not protected when treated 
with IL-22 [122]. Similarly, in CCl
4
-induced liver fibrogenesis, IL-22 is protective through 
induction of senescence in HSCs via STAT3 signaling pathway [123]. Moreover, IL-22 is also 
involved in the restoration of functional liver mass after organ damage. Liver progenitor cells 
have been shown to express IL-22R, and IL-22 derived from inflammatory cells induces pro-
liferation of liver progenitor cells [124].
4. Role of oxidative stress in liver fibrogenesis
Oxidative stress is caused by an imbalance between production of ROS and their elimination 
by anti-oxidant defenses [125]. As liver is an essential organ for detoxification and nutrients 
metabolism, it is more vulnerable to oxidative stress [125]. Oxidative stress-related molecules 
and pathways modulate tissue and cellular events involved in the liver fibrogenesis [126]. The 
generation of ROS plays a crucial role in producing liver damage and initiating liver fibro-
genesis [126]. Oxidative stress disrupts lipids, proteins and DNA, induces necrosis and apop-
tosis of hepatocytes, resulting in the initiation of fibrosis [127]. ROS stimulate the production 
of pro-fibrogenic mediators from KCs and circulating inflammatory cells. Remarkably, ROS 
directly activate HSCs. The elevated oxidative stress contributes to fibrogenesis via stimulat-
ing collagen production from activated HSCs and release of other pro-fibrogenic cytokines 
and growth factors [126, 128].
5. Role of microRNAs (miRNAs) in liver pathophysiology
miRNAs are a family of small non-coding RNAs (20–25 nucleotides in length) that control gene 
expression by binding to mRNAs to repress translation or induce mRNA cleavage [129]. Many 
researchers have reported that the unusual expression of miRNAs in liver tissue was related to 
the pathogenesis of liver disease of any etiology [130, 131]. Recently, miRNAs have been found 
to play fundamental roles in liver fibrosis, including those in HSC activation and ECM produc-
tion [132]. For example, miRNA-21 exhibits an important role in the pathogenesis and progres-
sion of liver fibrosis. A natural product 3,3′-Diindolylmethane (DIM) inhibits TGF-β signaling 
pathway by down-regulating the miRNA-21 expression in thioacetamide-induced experi-
mental liver fibrosis. Furthermore, DIM can suppress HSC activation via down-regulating 
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miRNA-21 levels in HSCs by inhibiting activity of the transcription factor AP-1 [133]. 
Inhibition of miRNA-21 also reduces liver fibrosis through concomitant reduction of CD24+ 
liver progenitor cells [134]. In mouse and human studies, the expression levels of miRNA-
199a, antisense miRNA-199a*, miRNA-200a, and miRNA-200b are found to be positively and 
significantly correlated with progression of liver fibrosis. Overexpression of these miRNAs 
dramatically increases the expression of fibrosis-related genes in HSCs [135]. Also, miRNA-
221 and miRNA-222 are up-regulated in human liver in a fibrosis progression-dependent 
manner [136]. Similarly, in isolated primary human liver cells, miRNA-571 is up-regulated 
in hepatocytes and HSCs in response to the pro-fibrogenic cytokine TGF-β [137]. miRNA-
214 appears to participate in the development of liver fibrosis by modulating the epidermal 
growth factor (EGF) receptor and TGF-β signaling pathways. Also, inhibition of miRNA-214 
by locked nucleic acid-antimiRNA-214 ameliorates liver fibrosis in PDGF c transgenic mice 
[138]. In addition, miRNA-214-5p may play crucial roles in HSC activation and progression 
of liver fibrosis. The overexpression of miRNA-214-5p in human stellate cells increases the 
expression of fibrosis-related genes such as MMP-2, MMP-9, α-SMA, and TGF-β1 [139].
miRNAs may also play anti-fibrogenic roles. It has been demonstrated that both miRNA-150 
and miRNA-194 inhibit HSC activation and ECM production in rats with liver fibrosis by 
decreasing the expression of c-myb (target for miRNA-150) and rac 1 (target for miRNA-194) 
[140]. Interestingly, miRNAs such as miRNA-19b, miRNA-29, miRNA-133a, and miRNA-
146a are significantly down-regulated in HSCs isolated from experimental animals with liver 
fibrosis, and restoration of these miRNAs alleviates fibrogenesis [47, 141, 142]. Moreover, 
miRNA-133a overexpression inhibits both human and murine primary HSCs proliferation 
and prevents the progression of liver fibrosis [142].
Multiple studies have proposed that miRNAs may serve as biomarkers for HSC activation 
and liver fibrosis progression, and can be possible candidates for future therapies targeting 
liver fibrosis/cirrhosis.
6. Pathogenesis of liver fibrosis/cirrhosis
Liver fibrosis and its end-stage consequence, cirrhosis, represent the final common pathway 
of almost all chronic liver diseases. Fibrosis and cirrhosis of the liver remain major medi-
cal problems with significant morbidity and mortality worldwide. Liver fibrosis is in fact 
a wound-healing response to liver injury and is characterized by accumulation of fibrotic 
scar tissue. Although the scar tissue formation is beneficial at first because it encapsulates 
the injury, the chronic activation of this healing process eventually progresses to advanced 
fibrosis/cirrhosis. This leads to altered vascular architecture and microcirculation, ischemia, 
and widespread hepatocyte cell death [143]. Also, in cirrhosis, collagen strands become so 
prevalent and divide the liver parenchyma into distinct structurally abnormal regenerative 
nodules, resulting in organ dysfunction [143].
In fact, liver damage leading to cirrhosis is the result of a complex mechanism involving, from 
direct toxic effects to a sustained inflammatory process, driving to the death of hepatocytes 
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via apoptosis and liver fibrosis, mediated by secretion of several cytokines [144]. The inflam-
matory reaction is the coordinated process by which the liver responds to local insults, trying 
to restore the hepatic architecture and function after acute liver injury [128]. However, if the 
liver is faced to a sustained local damage, the chronic inflammatory response gives rise to 
a progressive replacement of healthy liver tissue by non-functional fibrotic scar tissue. The 
imbalance between tissue regeneration and fibrosis determines the outcome toward health 
recovery or liver cirrhosis [144].
6.1. Imbalance between extracellular matrix synthesis and degradation
Liver fibrosis can be defined as a dynamic and highly integrated molecular, tissue and cel-
lular process regarded as the result of an imbalance between ECM synthesis and degradation. 
In the healthy liver, ECM is composed of several components such as collagens (mainly the 
interstitial types I, III, V, VI, and the basement membrane types IV, XV, XVIII, and XIX), gly-
coproteins (such as laminin isoforms and fibronectin), proteoglycans and elastin [145–147]. 
Normally, ECM components comprise less than 3% of the relative area of a liver tissue section 
and approximately 0.5% of the wet weight. During the development of liver fibrosis, there is 
a 5- to 10-fold increase in the content of collagenous and non-collagenous components, par-
ticularly of fibrillar collagen type I and III [146], and an increase of elastin, laminins, and pro-
teoglycans [148]. The total amount of ECM is not only dependent on the rate of synthesis but 
also largely on the balance between the matrix MMPs, and the TIMPs, especially TIMP-1 [15].
The MMPs are a family of zinc-dependent endopeptidases that can degrade both collagenous 
and non-collagenous components of ECM in the extracellular space [149]. MMP activity is 
regulated by TIMPs, which bind to MMPs, blocking their proteolytic activity. The MMPs and 
TIMPs play a crucial role in the fine regulation of the ECM turnover and the resulting increase 
in the TIMPs/MMPs ratio in liver promotes fibrosis by protecting accumulated matrix from 
degradation by MMPs (Figure 1) [8].
6.2. Mechanisms and mediators of liver fibrogenesis
Liver fibrosis, which is characterized by the excessive deposition of ECM (non-functional con-
nective tissue) components [150], involves both parenchymal and non-parenchymal cells, as 
well as infiltrating immune cells [151, 152]. Furthermore, several critical signaling pathways 
have important roles in liver fibrosis. The complex interactions between these signaling path-
ways and different cells contribute to the progression of liver fibrosis [153].
HSCs are central effectors of fibrogenesis although other cells and processes can make signifi-
cant contributions. In the healthy liver, HSCs are in a quiescent state with low proliferation rates, 
store dietary vitamin A, control the ECM synthesis, regulate the local vascular contractility, and 
serve as the pericytes for the sinusoidal endothelial cells. Damage to hepatocytes activates HSCs 
transformation into myofibroblast-like cells that play a fundamental role in the development 
of fibrotic liver response [14]. Myofibroblast-like cells with high proliferative capacity, without 
vitamin A, exhibit increased expression of α-SMA fibers [3]. These cells contribute to fibrosis by 
producing large amounts of ECM components and collagens (specifically type I) to encapsulate 
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the injury [152]. Although HSCs are classically considered to be a major source of myofibro-
blasts [154, 155], other cell types like portal myofibroblasts and cells recruited from the bone 
marrow also contribute to the expansion of the myofibroblast population observed during the 
liver injury [154]. Activated HSCs also secrete an increased amount of MMPs and their inhibi-
tors, TIMPs, which are necessary for the ECM remodeling [154, 156]. HSC activation leads to the 
up-regulation of TIMPs and TGF-β1 with the inhibition of MMP activity. The TIMP activation 
thus stimulates collagen type I synthesis and ECM deposition in the extracellular space [157]. 
Besides injured hepatocytes, hepatic macrophages (KCs), endothelial cells, and lymphocytes 
also drive HSC activation [158].
HSC activation is still the primary pathway leading to the liver fibrosis and it consists of two 
main stages: initiation and perpetuation (Figure 2) [126]. The initiation stage is related with 
the early changes in gene expression and phenotype that render the cells responsive to several 
cytokines and stimuli. Initiation of HSC activation is stimulated by several soluble factors such 
as oxidant stress signals (ROS), apoptotic bodies, and paracrine stimuli from neighboring cell 
types including hepatocytes, KCs, sinusoidal endothelium, and platelets [8, 72]. Hepatocytes 
Figure 1. Imbalances in ECM synthesis and degradation result in liver fibrosis. Regulation of degradation is determined 
by the balance between the activity of MMPs and TIMPs. The MMPs degrade both collagenous and non-collagenous 
components of ECM in the extracellular space. MMP activity is regulated by TIMPs, which bind to MMPs, blocking 
their proteolytic activity. Increase in the TIMPs/MMPs ratio in liver promotes fibrosis by protecting accumulated matrix 
from degradation by MMPs. ECM, extracellular matrix; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitor of 
metalloproteinases.
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are believed to represent a major source of ROS as well as of other oxidative stress-related 
reactive mediators or intermediates [1]. Hepatocyte apoptosis leads to the release of cellular 
contents such as DNA and ROS that activate KCs to release pro-inflammatory (such as TNF-α, 
IL-1β, IL-6, MCP-1) and pro-fibrogenic (especially TGF-β) factors [158]. Hepatocyte apoptosis 
following injury also promotes initiation of HSC activation through a process mediated by 
Fas, and this process may involve the TRAIL [159]. After stimulation by cytokines or engulf-
ment of apoptotic bodies, KCs stimulate matrix synthesis and cell proliferation through the 
actions of cytokines including TGF-β1 and ROS/lipid peroxides [64]. Endothelial cells are also 
likely to participate by conversion of TGF-β from the latent to the active, pro-fibrogenic form 
[126]. Platelets are another important source of paracrine stimuli, including PDGF, TGF-β1, 
and EGF [126]. On the other hand, perpetuation stage results from the effects of these stimuli 
on maintaining the activated phenotype and generating liver fibrosis. This stage involves 
Figure 2. Initiation, perpetuation, and regression of liver fibrogenesis involving HSCs. The pathways of HSC activation 
consist of initiation and perpetuation. Initiation is stimulated by soluble factors such as apoptotic bodies, oxidant stress 
signals (ROS), and paracrine stimuli from neighboring cell types. Perpetuation includes HSC activation (phenotypic 
switch from a quiescent type into an activated type) and related cellular changes such as proliferation, chemotaxis, 
fibrogenesis, contractility, and abnormal matrix degradation. Repetitive damage to liver causes perpetuation of activated 
HSCs in the liver. Activated HSCs produce excessive collagen, down-regulate release of MMPs and enhance expression 
of the physiological inhibitors of the MMPs (TIMPs). Imbalances in collagen synthesis and degradation result in liver 
fibrosis/cirrhosis. During regression, activated HSCs undergo apoptosis or inactivation if the cause of liver injury is 
removed. ROS, reactive oxygen species; KC, Kupffer cell; HSC, hepatic stellate cell; TNF-α, tumor necrosis factor-α; IL, 
interleukin; MCP-1, monocyte chemoattractant protein-1; TGF-β, transforming growth factor-β; TIMPs, tissue inhibitor 
of metalloproteinases; MMPs, matrix metalloproteinases; TRAIL, TNF-related apoptosis-inducing ligand.
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autocrine as well as paracrine cycles. It includes HSC activation and related cellular changes 
such as proliferation, chemotaxis, fibrogenesis, contractility, and matrix degradation [126]. 
Activated HSCs proliferate in response to various kinds of cytokines, chemokines, and growth 
factors such as TGF-β, EGF, and PDGF [2, 8]. TGF-β, which has been identified as the most 
pro-fibrotic cytokine, promotes expression of collagen type I by activated HSCs and inhibits 
ECM degradation through the expression of TIMPs [160]. In parallel, PDGF has emerged as 
the most potent proliferative cytokine for HSCs [8]. Also, activated HSCs show chemotac-
tic response, migrate toward damaged area and start to accumulate [3]. They express the 
cytoskeleton protein (α-SMA), equipping the cells with a contractile apparatus and collagens 
(especially type I) [12, 161, 162]. Thus, HSCs are able to constrict individual sinusoids as well 
as the entire fibrotic liver [3]. The net effect of these changes is to increase ECM deposition. 
In addition, cytokine release by HSCs can expand the inflammatory and fibrogenic tissue 
responses, and matrix proteases may hasten the replacement of normal matrix with fibrotic 
scar [126]. Briefly, activated HSCs are major effectors of liver fibrogenesis by integrating all 
incoming paracrine or autocrine signals released from both parenchymal and non-parenchy-
mal cells (pro-inflammatory cytokines, growth factors, chemokines, ROS, and others).
Chronic inflammation and fibrosis are inseparably linked and the interactions between immune 
cells, local fibroblasts and especially subsets of macrophages determine the outcome of liver 
injury [8]. Macrophage phenotype and function are critical determinants of fibrotic scarring 
or resolution of injury. Macrophages, which are typically categorized into classically activated 
(M1) or alternatively activated (M2) phenotypes, play dual roles in the progression and resolu-
tion of liver fibrosis [163]. Typically, M1 macrophages play a pro-inflammatory role in liver 
injury and produce inflammatory cytokines, while M2 macrophages exert an anti-inflammatory 
role during tissue repair and fibrosis. The imbalance of M1 and M2 macrophages mediates the 
progression and resolution of liver fibrosis [164]. During the early stages of liver injury, bone 
marrow-derived monocytes are extensively recruited to the liver and then differentiate into 
inflammatory macrophages (mostly M1 macrophages) to produce pro-inflammatory and pro-
fibrotic cytokines, thereby promoting inflammatory responses and HSC activation. Afterwards, 
recruited macrophages switch their phenotypes (mostly M2 macrophages) to secrete MMPs 
for the successful resolution in hepatic scar [153, 165, 166]. Therefore, a complicated interplay 
between M1 and M2 types of macrophages plays a critical role in fibrogenesis [128].
6.3. Liver fibrosis is potentially reversible
Liver fibrosis is thought to be a potentially reversible condition if the cause of liver injury is 
removed (such as virus suppression or alcohol absence) (Figure 2). Regression of liver fibrosis 
is associated either with elimination of activated HSCs via apoptosis or senescence or with 
reversion of activated HSCs to a more quiescent phenotype. It has been shown that HSCs are 
sensitive to Fas and TRAIL-mediated apoptosis, and natural killer cells can induce apoptosis 
of HSCs by a TRAIL-mediated mechanism [167]. Similarly, TRAIL expressed by KCs is also 
thought to mediate HSC apoptosis [168]. In addition, apoptosis of activated HSCs is for sure 
followed by a decrease in collagen production as well as a reduction in TIMP synthesis with 
an increase in the hepatic MMP expression [1]. Therefore, activated HSCs, the primary source 
of ECM, are the most attractable target for reversing liver fibrosis [169].
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7. Halofuginone
Halofuginone, a non-toxic and low molecular weight plant alkaloid [7-bromo-6-chloro-3-(3-
hydroxy-2-piperidine)-2-oxopropyl-4(3H)-quinazoline] (Figure 3) isolated from the roots 
of Dichroa febrifuga (Chinese medicinal plant), is used worldwide as an anti-parasitic drug 
in commercial poultry production [16]. At first, halofuginone was identified as a potent 
inhibitor of collagen type α1 gene expression and ECM deposition. At present, it is being 
evaluated in clinical trial for Duchenne muscular dystrophy, in which fibrosis is the main 
complication.
7.1. Halofuginone and its effect on collagen synthesis
Halofuginone was found to be a potent inhibitor of collagen type α1 gene expression [17], 
which was demonstrated in a broad range of cell types including rat, mouse, chicken, and 
human, both in vitro and in vivo [16–20]. The discovery of the inhibitory effect of halofuginone 
on collagen synthesis and ECM deposition has led to intensive studies that were aimed to 
control many diseases associated with excessive collagen accumulation, such as pulmonary, 
pancreatic and renal fibrosis [21–23], scleroderma and chronic graft-versus-host disease [24], 
post-operative peritendinous and abdominal adhesions [25, 26], urethral and esophageal 
strictures [27, 28], wound repair [29], burn injury [30], renal injury [31, 32], injury-induced 
arterial intimal hyperplasia [33], colitis [34], and liver fibrosis and cirrhosis [35–39]. Inhibition 
is independent of the route of administration (intraperitoneally, administered locally, or 
given orally).
Halofuginone was found to inhibit collagen type I synthesis but not that of type II [17] or III 
[170] in vitro. The inhibitor effect of halofuginone on collagen α1 synthesis appears not to be a 
direct effect but rather dependent on new protein synthesis, because concurrent treatment of 
fibroblasts with protein synthesis inhibitors blocks the suppressive effect of halofuginone on 
collagen α1 mRNA gene expression [18].
Because of the significant impact of fibrosis on human health, there is an unmet need for safe 
and effective therapies that directly target fibrosis. In animal models of fibrosis, regardless of 
the tissue, halofuginone had a minimal effect on collagen levels in the control (non-fibrotic) 
animals; however, it displayed a strong inhibitory effect in the fibrotic organs. This suggests 
that the regulation of the low-level expression of collagen type I genes differs from that of the 
Figure 3. Chemical structure of halofuginone.
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overexpression induced by the fibrogenic stimulus, which is usually an aggressive and rapid 
process [171]. Halofuginone mainly affects the stimulated collagen synthesis, therefore, when 
it is administered systemically, it is actually targeted to the desired fibrotic location without 
affecting collagen synthesis in other regions.
7.2. Halofuginone and TGF-β pathway
TGF-β is a “master switch” in chronic liver disease, being involved in all stages of the disease 
progression, from initial liver injury, inflammation, fibrosis, to cirrhosis and hepatocellular 
carcinoma at the end [172]. TGF-β signals through transmembrane receptor serine/threonine 
kinases to activate novel signaling intermediates called Smad proteins, which then modulate 
transcription of target genes [173]. TGF-β, signaling via Smad3, is the most pro-fibrogenic 
cytokine present in the liver and the major promoter of ECM synthesis [173, 174]. It induces 
pro-fibrotic cellular and transcriptional responses such as induction of the synthesis of ECM 
components, especially collagen, as well as fibronectin and laminin, and it inhibits the matrix 
degradation enzymes [175]. In various experimental fibrotic models, no effect of halofuginone 
was observed on the expression of the TGF-β receptors gene or on TGF-β levels [176–178]. This 
finding supports the hypothesis that the halofuginone target is down-stream in the TGF-β 
pathway. Halofuginone is an inhibitor of Smad3 phosphorylation down-stream of the TGF-β 
signaling pathway [177, 179, 180]. In chemically induced liver fibrosis, halofuginone affects 
TGF-β regulated genes through inhibition of Smad3 phosphorylation of activated HSCs [181]. 
It inhibits TGF-β-induced phosphorylation of Smad3 and also increases the expression of 
the inhibitory Smad7 in several cell types (such as fibroblasts, hepatic and pancreatic stellate 
cells, tumor cells and myoblasts) [178, 181–183]. The inhibition of Smad3 phosphorylation is 
associated with the halofuginone-dependent activation of Akt MAPK/ERK and p38 MAPK 
phosphorylation [182]. Thus, drugs that selectively target individual signaling pathways 
down-stream of the TGF-β receptor are likely to be more successful.
7.3. Halofuginone affects pre-existing fibrosis
Halofuginone affects fibrosis as a preventive agent when it was administered before or together 
with the fibrotic stimulus [21, 26, 27, 35, 184]. It can elicit resolution of established fibrosis, a capa-
bility that sets it apart from all other preventive anti-fibrotic agents. For example, in rats with 
established thioacetamide-induced liver fibrosis, addition of halofuginone to the diet results in 
almost complete resolution of the fibrotic condition as measured by hydroxyproline levels in the 
liver [36]. This is probably due to up-regulation of the collagen degradation pathway by inhibi-
tion of the TIMP-1, and activation of MMPs [43]. In addition, halofuginone given orally before 
fibrosis induction prevents the activation of most of the stellate cells and the remaining cells 
expressed low levels of collagen α1 gene, resulting in low levels of collagen [36]. Furthermore, 
halofuginone administration in low concentrations prior to and following partial hepatectomy 
in cirrhotic rats does not inhibit normal liver regeneration, despite the reduced levels of collagen 
type I mRNA [37]. When given to rats with established fibrosis, halofuginone causes significant 
reductions in α-SMA, TIMP-2, collagen type I gene expression, and collagen accumulation [37]. 
These animals demonstrate improved capacity for regeneration, suggesting the possible benefi-
cial use of halofuginone before and during fibrotic/cirrhotic liver regeneration.
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7.4. Halofuginone as an anti-fibrotic agent
In recent years, much attention was focused on halofuginone against liver fibrosis (Table 3). 
Although the exact anti-fibrotic mechanism of halofuginone is not well understood, it is found 
to be associated with inhibition of TGF-β signaling [179], which is known to inhibit mesengial 
Models Effects Mechanisms References
DMN-induced liver fibrosis/
cirrhosis in rats
Prevents liver cirrhosis Prevents increase in collagen type I 
gene expression
[35]
TAA-induced liver fibrosis in 
rats
Causes almost complete 
resolution of fibrosis
Reduces collagen levels, collagen 
α1(I) gene expression, TIMP-2 
content, and SMA-positive cells
[36]
TAA-induced liver cirrhosis 
in rats
Improves liver regeneration Reduces α-SMA, TIMP-2, collagen 
type I gene expression, and 
collagen accumulation
[37]
ConA-induced liver fibrosis 
in rats
Prevents liver fibrosis Decreases Th17 cell differentiation 
and its related cytokines 
production
[38]
ConA-induced liver fibrosis 
in rats
Attenuates liver fibrosis Suppresses synthesis of collagen 
1, α-SMA and TIMP-2; down-
regulates TGF-β1/Smad3 signaling 
pathway; decreases pro-
inflammatory cytokines
[39]
TAA-induced liver fibrosis in 
rats
Up-regulates MMP-3 and 
-13 and down-regulates 
TIMP-1 (in vivo); inhibits HSC 
proliferation and migration 
(in vitro)
Activates p38 MAPK and NF-κB [43]
TAA-induced liver fibrosis in 
rats
Inhibits HSC activation and 
collagen synthesis; prevents 
activation of TGF-β-dependent 
genes
Inhibits Smad3 phosphorylation [181]
TAA-induced liver fibrosis in 
rats
Affects cross-talk between 
hepatocytes and HSCs
Up-regulates synthesis and 
secretion of IGFBP-1
[192]
TAA-induced liver fibrosis in 
rats
Prevents liver fibrosis and 
improves cirrhotic liver 
regeneration
Increases expression of early 
genes of regeneration (PRL-1 and 
IGFBP-1)
[193]
Human hepatoma cell injected 
mice
Suppresses tumor growth Increases IFN-γ and IL-2 [196]
Diethylnitrosamine and 
N-nitrosomorpholine-induced 
HCC in rats
Suppresses lung metastasis Inhibits MMP [197]
Abbreviations: DMN, dimethylnitrosamine; TAA, thioacetamide; TIMP, tissue inhibitor of metalloproteinase; SMA, 
smooth muscle actin; ConA, Concanavalin A; Th17, T helper 17; TGF-β, transforming growth factor-β; MMP, matrix 
metalloproteinase; HSC, hepatic stellate cell; p38 MAPK, p38 mitogen-activated protein kinase; NF-κB, nuclear factor-
κB; IGFBP-1, insulin-like growth factor binding protein-1; PRL-1, tyrosine phosphatase; IFN-γ, interferon-γ; IL-2, 
interleukin-2; HCC, hepatocellular carcinoma.
Table 3. Effects of halofuginone in various experimental liver diseases.
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cell proliferation and ECM deposition [185]. In several animal models of fibrosis, in which 
excess collagen is the characteristic of the disease, halofuginone prevents transition of the 
fibroblasts to myofibroblasts by inhibition of Smad3 phosphorylation down-stream of the 
TGF-β signaling pathway [186, 187], thereby inhibits collagen synthesis [186]. Halofuginone 
also regulates cell growth and differentiation, apoptosis, cell migration, and immune cell func-
tion [41]. It prevents concanavalin A-induced liver fibrosis by affecting Th17 cell differentia-
tion, which suggests a direct link between the myofibroblasts/fibrosis pathway and the Th17 
pro-inflammatory pathway [38]. Th17 cells, a distinct subset of CD4+ T cells with IL-17 as their 
major cytokine, orchestrate the pathogenesis of inflammation [171]. It has been suggested 
that halofuginone-dependent inhibition of fibrosis includes selective inhibition of the Th17 
cell development by activating the amino acid starvation response [188, 189]. Halofuginone 
activates the amino acid starvation response by directly inhibiting the prolyl-tRNA synthetase 
activity of glutamyl-prolyl-tRNA synthetase [190]. Furthermore, addition of exogenous pro-
line reverses a broad range of halofuginone-induced cellular effects, indicating that glutamyl-
prolyl-tRNA synthetase-inhibition underlies the therapeutic activities of halofuginone [190]. 
TGF-β is required for facilitation of differentiation of the inflammatory Th17 cell subset [191], 
which suggests the presence of a connection between the TGF-β signaling inhibition and the 
amino acid starvation response [187]. Treatment with halofuginone also effectively inhibits 
the delayed-type hypersensitivity response, indicating suppression of T cell–mediated inflam-
mation in vivo [42]. Moreover, it was shown that halofuginone is a potent inhibitor of NF-κB, 
pro-inflammatory cytokines, and p38 MAPK phosphorylation in activated T cells in vitro [42]. 
Also, submicromolar concentrations of halofuginone inhibit HSC proliferation and migration 
and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and 
NF-κB. The remarkable induction of MMP-3 and -13 makes halofuginone a promising agent 
for anti-fibrotic combination therapies [43]. Halofuginone also affects the cross-talk between 
the hepatocytes and the HSCs by up-regulating the synthesis and secretion of insulin-like 
growth factor binding protein-1 (IGFBP-1), which inhibits HSC migration [192]. It also affects 
the expression of early genes of liver regeneration, IGFBP-1 whose synthesis and secretion is 
regulated in part by TGF-β [192] and tyrosine phosphatase (PRL-1) whose synthesis is regu-
lated by transcription factor early growth response-1 (Egr-1) probably via TGF-β [193].
7.5. Anti-tumoral role of halofuginone
In many types of tumor, there is a strong relationship between tissue fibrosis and increased 
risk of tumor development. For example, the leading risk factor for hepatocellular carcinoma 
is liver cirrhosis, and its associated inflammation, regeneration, and fibrosis [194, 195]. Tumor 
cells develop and metastasize more effectively in fibrotic tissues; therefore, any reduction in 
tissue fibrosis reduces the risk of cancer [171]. Halofuginone reduces tumor growth and mor-
tality in xenograph mice implanted with human hepatoma cells [196]. In diethylnitrosamine 
and N-nitrosomorpholine-induced, spontaneously metastasizing hepatocellular carcinoma, 
halofuginone suppresses lung metastasis in rats through MMP inhibition [197]. Moreover, 
halofuginone treatment results in effective inhibitory effects on the cascade of events leading 
to angiogenesis (formation of new blood vessels), such as abrogation of endothelial cell MMP-2 
expression, basement membrane invasion, capillary tube formation, vascular sprouting, and 
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deposition of sub-endothelial ECM in vitro [171]. Inhibition of angiogenesis is mostly accom-
panied by inhibition of the fibroblasts to myofibroblasts transition, reduction in tumor stroma 
ECM, and inhibition of tumor growth [171]. The high effectiveness of halofuginone in reducing 
fibrosis, which affects tumor growth and tissue regeneration in the liver, arises from its dual 
role in inhibiting the TGF-β signaling and Th17 cell development [187].
8. Conclusion
Fibrosis is a pathological process associated with excessive ECM deposition that leads to 
destruction of organ architecture and function. Fibrosis contributes enormously to deaths 
worldwide; thus, effective therapies are of a great need. Halofuginone has great potential as 
an anti-fibrotic therapeutic. Systemic administration of halofuginone in animal models and 
humans is well tolerated [24]. Additionally, in most animal models of fibrosis, halofuginone 
has a minimal effect on collagen levels in non-fibrotic animals, while exerting strong inhibi-
tory effects in fibrotic organs. It mainly affects stimulated collagen synthesis without altering 
the usual low physiological level of collagen expression. Because halofuginone inhibits col-
lagen type I synthesis on the transcriptional level and reduces ECM deposition, it is a promis-
ing candidate for treatment of diseases associated with excessive ECM, such as liver fibrosis/
cirrhosis. Thus, halofuginone meets the criteria as a promising anti-fibrotic drug for further 
evaluation in the treatment of liver fibrosis/cirrhosis.
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